静脉补充铁剂治疗慢性心力衰竭合并贫血患者的疗效观察

目的：观察静脉补充铁剂治疗慢性心力衰竭（CHF）合并贫血患者的疗效。方法：以CHF合并贫血患者为研究对象,随机分为静脉组与口服组,各68例。比较两组治疗3个月后和治疗6个月后的临床疗效、血红蛋白、铁蛋白、N末端脑利钠肽原（Nt-proBNP）、心功能分级、6min步行距离（6MWD）和药品不良反应的差异。结果：静脉组总有效率（94.12%）显著高于口服组（82.35%）,差异有统计学意义（P〈0.05）;治疗3个月后和治疗6个月后,两组患者的血红蛋白、铁蛋白、Nt-proBNP、心功能分级和6MWD均较同组治疗前显著改善（P〈0.05）,且静脉组改善程度均优于口服组（P〈0.05）;静脉组与口服组的总不良反应发生率分别为10.29%、11.76%,差异无统计学意义（P〉0.05）。结论：铁剂静脉给药治疗CHF合并贫血疗效优于口服给药。

Efficacy Observation of Intravenous Iron Supplement in the Treatment of Chronic Heart Failure Patients with Anemia

OBJECTIVE： To observe therapeutic efficacy of intravenous iron supplement in the treatment of chronic heart failure （CHF） patients with anemia. METHODS： CHF patients with anemia were regarded as subjects and randomly divided into intravenous administration group and oral administration group with 68 cases in each group. The clinical efficacy, hemoglobin, ferritin, N-terminal brain natriuretic peptide （Nt-proBNP）, cardiac function classification, six-minute walking distance （6 MWD） and adverse drug reaction were compared between 2 groups after 3 months and 6 months of treatment. RESULTS： The total effective rate of intravenous administration group （94.12%） was significantly higher than that of oral administration group （82.35%）, there was statistical significance （P〈0.05）. After three and six months of treatment, the hemoglobin, ferritin, Nt-proBNP, cardiac function and 6MWD were improved significantly in 2 groups, compared with before treatment; but the improvement of above index in intravenous administration group were better than in oral administration group, there was statistical significance （P〈0.05）. The incidence of ADR in 2 groups were 10.29% and 11.76%, there was no statistical significance （P〉0.05）. CONCLUSIONS： Therapeutic efficacy of intravenous iron supplement is better than oral administration in the treatment of CHF patients with anemia.